ISSN: 1307-5888 | E-ISSN: 2757-7392 | Contact
First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort
1Department of Infectious Diseases and Clinical Microbiology, Erzurum Training and Research Hospital, Erzurum, Turkiye
2Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkiye
3Department of Microbiology, Yildirim Beyazit University School of Medicine, Ankara, Turkiye
4Department of Infectious Diseases and Clinical Microbiology, Inonu University School of Medicine, Malatya, Turkiye
5Department of Gastroenterology, Inonu University School of Medicine, Malatya, Turkiye
6Department of Infectious Diseases and Clinical Microbiology, Gaziantep University School of Medicine, Gaziantep, Turkiye
7Department of Infectious Diseases and Clinical Microbiology, Cukurova University School of Medicine, Adana, Turkiye
8Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Turkiye
9Department of Infectious Diseases and Clinical Microbiology, Gazi University School of Medicine, Ankara, Turkiye
10Department of Infectious Diseases and Clinical Microbiology, Sanliurfa Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkiye
11Department of Infectious Diseases and Clinical Microbiology, Mersin University School of Medicine, Mersin, Turkiye
12Department of Infectious Diseases and Clinical Microbiology, Sutcu Imam University School of Medicine, Kahramanmaras, Turkiye
13Department of Infectious Diseases and Clinical Microbiology, Akdeniz University School of Medicine, Antalya, Turkiye
14Department of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, Batman, Turkiye
15Department of Infectious Diseases and Clinical Microbiology, Gazi Yasargil Training and Research Hospital, Diyarbakir16Department of Gastroenterology, Turkiye; Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkiye
16Department of Gastroenterology, Turkiye; Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkiye
17Department of Infectious Diseases and Clinical Microbiology, Firat University School of Medicine, Elazig, Turkiye
18Department of Pediatrics, Dicle University School of Medicine, Diyarbakir, Turkiye
19Department of Public Health, Istanbul University School of Medicine, Istanbul, Turkiye
20Freelance Pharmacist, Batman, Turkiye
21Department of Infectious Diseases and Clinical Microbiology, Dicle University School of Medicine, Diyarbakir, Turkiye
Hepatology Forum 2023; 4(2): 61-68 DOI: 10.14744/hf.2022.2022.0043 PMCID: PMC10209973
Full Text PDF

Abstract

Background and Aim: In chronic hepatitis B infection, antiviral therapy significantly reduces the incidence of complications. This study aimed to present real-life 12-month effectiveness and safety data for TAF.
Material and Methods: This Pythagoras Retrospective Cohort Study in-cluded patients from 14 centers in Turkiye. The study presents 12-month results of 480 patients treated with TAF as initial therapy or after switching from another antiviral drug.
Results: The study shows treatment of about 78.1% patients with at least one antiviral agent (90.6% tenofovir disoproxil [TDF]). The rate of unde-tectable HBV DNA increased in both treatment-experienced and naive pa-tients. In TDF-experienced patients, the rate of alanine transaminase (ALT) normalization increased slightly (1.6%) within 12 months, but the change was not statistically significant (p=0.766). Younger age, low albumin, and high body mass index and cholesterol were identified as risk factors for abnormal ALT after 12 months, but no linear relationship was detected. In TDF-experienced patients, renal and bone function indicators showed sig-nificant improvement three months after the transition to TAF and remained stable for 12 months.
Conclusion: Real-life data demonstrated effective virological and bio-chemical responses with TAF therapy. After switching to TAF treat-ment, gains in kidney and bone functions were achieved in the early period